Peptide Drug

DRAVP ID DRAVPc068

Name Grazoprevir

Sequence Not available

Molecular Formula C38H50N6O9S

Condition/Disease hepatitis C virus infections.

Group Approved

Type Cyclic peptidomimetic

Description Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy in combination with Elbasvir for genotypes 1a, 1b, and 4 of Hepatitis C.

Active sequence/Structure

DrugBank Accession Number DB11575

Pubchem ID 44603531

CHEMBL ID CHEMBL2063090

UNII 8YE81R1X1J

CAS 1350514-68-9

Reference 25585348 28497432 22615282 24900473 24666106

NCT Number	Study Title	Condition/Disease	Status	Phase	Sponsor
NCT06172660	Real-World Effectiveness of Perinatal RSV Immunoprophylaxis	RSV Infection	Recruiting		Yale University
NCT04840849	Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults (PK/ADA)	Evaluate PK Profile	Completed	Phase 1	AstraZeneca
NCT03420300	EBR/GZR for HCV-1b Patients Receiving Hemodialysis	Hepatitis C	Completed	Phase 4	National Taiwan University Hospital

NCT Number

Study Title

Condition/Disease

Status

Phase

Sponsor

NCT06172660

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

RSV Infection

Recruiting

Yale University

NCT04840849

Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults (PK/ADA)

Evaluate PK Profile

Completed

Phase 1

AstraZeneca

NCT03420300

EBR/GZR for HCV-1b Patients Receiving Hemodialysis

Hepatitis C

Completed

Phase 4

National Taiwan University Hospital